1
|
Sleumer B, Kema IP, van de Merbel NC. Quantitative bioanalysis of proteins by digestion and LC-MS/MS: the use of multiple signature peptides. Bioanalysis 2023; 15:1203-1216. [PMID: 37724471 DOI: 10.4155/bio-2023-0129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/20/2023] Open
Abstract
The use of multiple signature peptides for the quantification of proteins by digestion and LC-MS/MS is reviewed and evaluated here. A distinction is made based on the purpose of the use of multiple peptides: confirmation of the protein concentration, discrimination between different protein forms or species and in vivo biotransformation. Most reports that describe methods with at least two peptides use these for confirmation, but it is not always mentioned how the peptides are used and how possible differences in concentration between the peptides are handled. Differences in concentration are often reported in the case of monitoring different protein forms or in vivo biotransformation, and this offers insight into the biological fate of the protein.
Collapse
Affiliation(s)
- Bas Sleumer
- ICON Bioanalytical Laboratories, Amerikaweg 18, 9407 TK, Assen, The Netherlands
- Department of Analytical Biochemistry, University of Groningen, A Deusinglaan 1, 9700 AV Groningen, The Netherlands
- Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, EA61, PO Box 30.001, 9700 RB Groningen, The Netherlands
| | - Ido P Kema
- Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, EA61, PO Box 30.001, 9700 RB Groningen, The Netherlands
| | - Nico C van de Merbel
- ICON Bioanalytical Laboratories, Amerikaweg 18, 9407 TK, Assen, The Netherlands
- Department of Analytical Biochemistry, University of Groningen, A Deusinglaan 1, 9700 AV Groningen, The Netherlands
| |
Collapse
|
2
|
Yin F, Adhikari D, Peay M, Cortes D, Garada M, Shane Woolf M, Ma E, Lebarbenchon D, Mylott W, Dyszel M, Harriman S, Pinkas J. Development and validation of a hybrid immunoaffinity LC-MS/MS assay for quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2023; 1228:123844. [PMID: 37579604 DOI: 10.1016/j.jchromb.2023.123844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2023] [Revised: 07/24/2023] [Accepted: 07/25/2023] [Indexed: 08/16/2023]
Abstract
A hybrid immunoaffinity LC-MS/MS assay was developed and validated for the quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma. PYX-201 was proteolyzed using trypsin, and a characteristic peptide fragment PYX-201 P1 with ten amino acids IPPTFGQGTK from the complementarity-determining regions (CDRs) was used as a surrogate for the quantitation of the TAb from PYX-201. Stable isotope labelled (SIL) peptide I(13C6, 15N)PPTFG(13C9, 15N)QGTK was used as the internal standard (IS). We performed chromatographic analysis using a Waters Acquity BEH Phenyl column (2.1 mm × 50 mm, 1.7 µm). Quantification of PYX-201 TAb was carried out on a Sciex triple quadrupole mass spectrometer API 6500 using multiple reaction monitoring (MRM) mode with positive electrospray ionization. To validate PYX-201 TAb, a concentration range of 0.0500 µg/mL to 20.0 µg/mL was used, yielding a correlation coefficient (r) of ≥ 0.9947. For intra-assay measurements, the percent relative error (%RE) ranged from -23.2% to 1.0%, with a coefficient of variation (%CV) of ≤ 14.2%. In terms of inter-assay measurements, the %RE was between -10.5% and -5.7%, with a %CV of ≤ 12.7%. The average recovery of the analyte was determined to be 81.4%, while the average recovery of the internal standard (IS) was 97.2%. Furthermore, PYX-201 TAb demonstrated stability in human plasma and human whole blood under various tested conditions. This assay has been successfully applied to human sample analysis to support a clinical study.
Collapse
Affiliation(s)
- Feng Yin
- Department of Nonclinical Research, Pyxis Oncology, Inc, 321 Harrison Avenue, Suite 1, Boston, MA 02118, USA
| | - Diana Adhikari
- Department of Nonclinical Research, Pyxis Oncology, Inc, 321 Harrison Avenue, Suite 1, Boston, MA 02118, USA
| | - Marlking Peay
- Chromatographic Services - Research & Development, Biologics by LC-MS/MS, PPD Laboratory Services (a part of ThermoFisher Scientific), 8700 Quioccasin Road, Henrico, VA 23229, USA
| | - Diego Cortes
- Chromatographic Services - Research & Development, Biologics by LC-MS/MS, PPD Laboratory Services (a part of ThermoFisher Scientific), 8700 Quioccasin Road, Henrico, VA 23229, USA
| | - Mohammed Garada
- Chromatographic Services - Research & Development, Biologics by LC-MS/MS, PPD Laboratory Services (a part of ThermoFisher Scientific), 8700 Quioccasin Road, Henrico, VA 23229, USA
| | - M Shane Woolf
- Chromatographic Services - Research & Development, Biologics by LC-MS/MS, PPD Laboratory Services (a part of ThermoFisher Scientific), 8700 Quioccasin Road, Henrico, VA 23229, USA
| | - Eric Ma
- Chromatographic Services - Research & Development, Biologics by LC-MS/MS, PPD Laboratory Services (a part of ThermoFisher Scientific), 8700 Quioccasin Road, Henrico, VA 23229, USA
| | - Diane Lebarbenchon
- Chromatographic Services - Research & Development, Biologics by LC-MS/MS, PPD Laboratory Services (a part of ThermoFisher Scientific), 8700 Quioccasin Road, Henrico, VA 23229, USA
| | - William Mylott
- Chromatographic Services - Research & Development, Biologics by LC-MS/MS, PPD Laboratory Services (a part of ThermoFisher Scientific), 8700 Quioccasin Road, Henrico, VA 23229, USA
| | - Mike Dyszel
- Department of Project Management, Pyxis Oncology, Inc, 321 Harrison Avenue, Suite 1, Boston, MA 02118, USA
| | - Shawn Harriman
- Department of Nonclinical Research, Pyxis Oncology, Inc, 321 Harrison Avenue, Suite 1, Boston, MA 02118, USA.
| | - Jan Pinkas
- Department of Nonclinical Research, Pyxis Oncology, Inc, 321 Harrison Avenue, Suite 1, Boston, MA 02118, USA.
| |
Collapse
|
3
|
Generic MS-based method for the bioanalysis of therapeutic monoclonal antibodies in nonclinical studies. Bioanalysis 2020; 12:231-243. [DOI: 10.4155/bio-2019-0253] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Aim: A generic bioanalytical method was developed to quantify therapeutic IgG1 monoclonal antibodies (mAbs) in mouse sera by combining an easy sample preparation method with LC/MS using selected reaction monitoring. Materials & methods: Rituximab and trastuzumab were used as model mAbs. A synthetic stable isotope-labeled peptide or a stable isotope-labeled mAb was used as an internal standard. The method feasibility was evaluated by a collaborative study involving six laboratories. Results: The calibration curve ranged from 1.0 to 1000.0 μg/ml (correlation coefficient >0.99). The validation parameters including selectivity, linearity of calibration curve, accuracy and precision met the predefined acceptance criteria. Conclusion: Our method is a useful bioanalytical method for the quantification of therapeutic IgG mAbs in nonclinical animal studies.
Collapse
|
4
|
Pharmacokinetic Characterization and Tissue Distribution of Fusion Protein Therapeutics by Orthogonal Bioanalytical Assays and Minimal PBPK Modeling. Molecules 2020; 25:molecules25030535. [PMID: 31991858 PMCID: PMC7037219 DOI: 10.3390/molecules25030535] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Revised: 01/15/2020] [Accepted: 01/22/2020] [Indexed: 02/07/2023] Open
Abstract
Characterization of pharmacokinetic (PK) properties and target tissue distribution of therapeutic fusion proteins (TFPs) are critical in supporting in vivo efficacy. We evaluated the pharmacokinetic profile of an investigational TFP consisting of human immunoglobulin G4 fused to the modified interferon alpha by orthogonal bioanalytical assays and applied minimal physiologically based pharmacokinetic (PBPK) modeling to characterize the TFP pharmacokinetics in mouse. The conventional ligand binding assay (LBA), immunocapture-liquid chromatography/tandem mass spectrometry (IC-LC/MS) detecting the human IgG4 peptide or the interferon alpha peptide were developed to measure the TFP concentrations in mouse plasma and tumor. The minimal PBPK model incorporated a tumor compartment model was used for data fitting. The plasma clearance measured by LBA and IC-LC/MS was comparable in the range of 0.5–0.6 mL/h/kg. However, the tumor exposure measured by the generic human IgG4 IC-LC/MS was significantly underestimated compared with the interferon alpha specific IC-LC/MS and LBA. Furthermore, the minimal PBPK model simultaneously captured the relationship between plasma and tissue exposure. We proposed the streamlined practical strategy to characterize the plasma exposure and tumor distribution of a TFP by both LBA and IC-LC/MS. The minimal PBPK modeling was established for better understanding of pharmacokinetic profile of investigational TFPs in the biotherapeutic discovery.
Collapse
|
5
|
Yuan M, Ismaiel O, Mylott W. Hybrid Ligand Binding Immunoaffinity-Liquid Chromatography/Mass Spectrometry for Biotherapeutics and Biomarker Quantitation: How to develop a hybrid LBA-LC-MS/MS method for a protein? ACTA ACUST UNITED AC 2019. [DOI: 10.17145/rss.19.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
6
|
Determination of Cetuximab in Plasma by Liquid Chromatography-High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled 13C,15N-Cetuximab Internal Standard. Ther Drug Monit 2019; 41:467-475. [PMID: 31306393 DOI: 10.1097/ftd.0000000000000613] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
BACKGROUND Cetuximab (CTX) is a chimeric IgG1 Kappa monoclonal antibody used to treat head and neck cancer and colorectal cancer. Previous clinical studies indicated that the pharmacokinetics of CTX influences patient survival. Thus, individualizing CTX treatment by measuring trough levels of the drug in plasma could have a major impact on clinical efficacy. METHODS To measure these levels, a full-length stable isotope-labeled CTX standard was used in a generic, rapid, and high-throughput sample preparation protocol based on IgG capture followed by trypsin digestion, on-line solid-phase extraction cleanup, and liquid chromatography-high resolution mass spectrometry (LC-HRMS). RESULTS The optimized method displayed good analytical performance and was linear over a range from 5 to 150 mcg/mL. The within-run and between-run imprecision of the assay were equal to or less than 10%, for 6 replicates at 3 different concentrations and for runs performed on 5 separate days. The plasma CTX concentrations in 19 patients were also determined. CONCLUSIONS The results showed that quantification of mAb in clinical samples does not strictly require a tandem mass spectrometry system, and LC-HRMS is also relevant in this context. This first study implementing a quantitative LC-HRMS assay with a specific stable isotope-labeled mAb internal standard paves the way for more robust clinical monitoring of anticancer mAbs.
Collapse
|
7
|
Protein quantification by LC–MS: a decade of progress through the pages of Bioanalysis. Bioanalysis 2019; 11:629-644. [DOI: 10.4155/bio-2019-0032] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Over the past 10 years, there has been a remarkable increase in the use of LC–MS for the quantitative determination of proteins, and this technique can now be considered an established bioanalytical platform for the quantification of macromolecular drugs and biomarkers, next to the traditional ligand-binding assays. Many researchers have contributed to the field and helped improve both the technical possibilities of LC–MS-based workflows and our understanding of the meaning of the results that are obtained. As a tribute to Bioanalysis, which has published many important contributions, this report gives a high-level overview of the most important trends in the field of protein LC–MS, as published in this journal since its inauguration a decade ago. It describes the major technical developments with regard to sample handling, separation and MS detection of both digested and intact protein analysis. In addition, the relevance of the complex structure and in vivo behavior of proteins is discussed and the effect of protein–protein interactions, biotransformation and the occurrence of isoforms on the analytical result is addressed.
Collapse
|
8
|
Bults P, Spanov B, Olaleye O, van de Merbel NC, Bischoff R. Intact protein bioanalysis by liquid chromatography – High-resolution mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1110-1111:155-167. [DOI: 10.1016/j.jchromb.2019.01.032] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2018] [Revised: 01/20/2019] [Accepted: 01/31/2019] [Indexed: 02/07/2023]
|
9
|
Xu L, Packer LE, Li C, Abdul-Hadi K, Veiby P. A generic approach for simultaneous measurements of total antibody and cleavable antibody-conjugated drug by LC/MS/MS. Anal Biochem 2017; 537:33-36. [DOI: 10.1016/j.ab.2017.08.024] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Revised: 08/10/2017] [Accepted: 08/30/2017] [Indexed: 11/16/2022]
|
10
|
Novel strategy using tryptic peptide immunoaffinity-based LC–MS/MS to quantify denosumab in monkey serum. Bioanalysis 2017; 9:1451-1463. [DOI: 10.4155/bio-2017-0106] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Aim: Denosumab is a recombinant fully human IgG2 that has a high affinity and specificity for human RANKL. Commercially available RANKL labeled with an Fc fragment cannot be used to establish an indirect ELISA. To characterize denosumab pharmacokinetic a robust and accuracy method should be developed urgently. Results: In this study, an immunoaffinity enrichment method coupled with LC–MS/MS was established. The LC–MS/MS method acquired a linear range from 0.1 to 30 μg/ml. The intra- and inter-run precision (CV%) was within 11.5 and 10.5%, respectively. More importantly, the LC–MS/MS pharmacokinetic data were consistent with ELISA. Conclusion: This approach accelerated the quantification, reduced the costs and provided an alternative in case of lacking the special antigen to denosumab or a RANKL-biotinylated reagent.
Collapse
|
11
|
Do we have a mature LC–MS/MS methodology for therapeutic monoclonal antibody bioanalysis? Bioanalysis 2017; 9:1289-1292. [DOI: 10.4155/bio-2017-4983] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
|
12
|
Osaki F, Tabata K, Oe T. Quantitative LC/ESI-SRM/MS of antibody biopharmaceuticals: use of a homologous antibody as an internal standard and three-step method development. Anal Bioanal Chem 2017; 409:5523-5532. [PMID: 28710515 DOI: 10.1007/s00216-017-0488-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Revised: 05/29/2017] [Accepted: 06/22/2017] [Indexed: 11/27/2022]
Abstract
Monoclonal antibody-based therapeutic agents (antibody drugs) have attracted considerable attention as a new type of drug. Concomitantly, the use of quantitative approaches for characterizing antibody drugs, such as liquid chromatography (LC)-mass spectrometry (MS), has increased. Generally, selective quantification of antibody drugs is done using unique peptides from variable regions (V H and V L) as surrogate peptides. Further, numerous internal standards (ISs) such as stable isotope-labeled (SIL)-intact proteins and SIL-surrogate peptides are used. However, developing LC-MS methodology for characterizing antibody drugs is time-consuming and costly. Therefore, LC-MS is difficult to apply for this purpose, particularly during the drug discovery stage when numerous candidates must be evaluated. Here, we demonstrate an efficient approach to developing a quantitative LC/electrospray ionization (ESI)-selected reaction monitoring (SRM)/MS method for characterizing antibody drugs. The approach consists of the following features: (i) standard peptides or SIL-IS are not required; (ii) a peptide from the homologous monoclonal antibody serves as an IS; (iii) method development is monitored using a spiked plasma sample and one quantitative MS analysis; and (iv) three predicted SRM assays are performed to optimize quantitative SRM conditions such as transition, collision energy, and declustering potential values. Using this strategy, we developed quantitative SRM methods for infliximab, alemtuzumab, and bevacizumab with sufficient precision (<20%)/accuracy (<±20%) for use in the drug discovery stage. We have also demonstrated that choosing a higher homologous peptide pair (from analyte mAb/IS mAb) is necessary to obtain the sufficient precision and accuracy. Graphical abstract ᅟ.
Collapse
Affiliation(s)
- Fumio Osaki
- Department of Bio-analytical Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-aoba, Aoba-ku, Sendai, Miyagi, 980-8578, Japan
- Analysis & Pharmacokinetics Research Labs, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan
| | - Kenji Tabata
- Analysis & Pharmacokinetics Research Labs, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan
| | - Tomoyuki Oe
- Department of Bio-analytical Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-aoba, Aoba-ku, Sendai, Miyagi, 980-8578, Japan.
| |
Collapse
|
13
|
Phillip A, Thierry W, Christian L, Anja B, Jochen E, Thomas M, Claudia P, Coralie E, Olivier H. Production and application of high quality stable isotope-labeled human immunoglobulin G1 for mass spectrometry analysis. J Labelled Comp Radiopharm 2017; 60:160-167. [DOI: 10.1002/jlcr.3486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Revised: 11/11/2016] [Accepted: 12/06/2016] [Indexed: 11/06/2022]
Affiliation(s)
| | - Wolf Thierry
- Novartis Pharma AG; DMPK, DMBA-BA; Basel Switzerland
| | | | | | | | | | | | | | - Heudi Olivier
- Novartis Pharma AG; DMPK, DMBA-BA; Basel Switzerland
| |
Collapse
|
14
|
3-(4-Hydroxyphenyl)propionic acid: the forgotten detection substrate for ligand-binding assay-based bioanalysis. Bioanalysis 2017; 9:407-418. [DOI: 10.4155/bio-2016-0225] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Ligand-binding assays are ideal for routine bioanalysis, but we reason that the straightforward replacement of the conventional chromogenic horseradish peroxidase substrate, 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid, of a routinely used preclinical immunoassay to detect hIgG, with the fluorogenic 3-(4-hydroxyphenyl)propionic acid would broaden the narrow dynamic range. The replacement leads to a sensitivity of 0.47 (minimum required dilution [MRD] 10) and 1.02 (MRD 50) ng/ml, and dynamic ranges of 3.3 (MRD 10) and 3.6 (MRD 50) orders of magnitude, and thereby had improved sensitivity and dynamic range compared with other conventional colorimetric ELISAs, other ligand-binding assay technologies or LC–MS assays. Improvements in sensitivity and dynamic range were achieved for the sera of horse, mice and monkeys without assay optimization.
Collapse
|
15
|
Li W, Lin H, Fu Y, Flarakos J. LC–MS/MS determination of a human mAb drug candidate in rat serum using an isotopically labeled universal mAb internal standard. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1044-1045:166-176. [DOI: 10.1016/j.jchromb.2016.12.044] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2016] [Revised: 11/21/2016] [Accepted: 12/31/2016] [Indexed: 01/07/2023]
|
16
|
From patient to tube: the importance of physiologically relevant quantitative bioanalytical assays. Bioanalysis 2016; 8:2595-2604. [PMID: 27884077 DOI: 10.4155/bio-2016-0214] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Circulating drug concentrations (clinical or preclinical) underly many interactions between industry and regulators; expressing safety coverage, pharmacokinetic-pharmacodynamic relationships or defining bioequivalence and dosing regimens. Accurate and precise measurement of these circulating concentrations is pivotal to the evolution and validation of any bioanalytical method that supports regulatory interactions. Since the bioanalyst is presented with a sub-aliquot of sampled biological matrix, how do they ensure this aliquot reflects the concentration in the subject at the time of collection? Here we share experiences from project support (internal and at CROs) that suggests we need to be ever vigilant translating the needs of bioanalysis with those of project teams. The simple mantra is for bioanalytical measurements to be physiologically relevant to the patient.
Collapse
|
17
|
Application of high-resolution MS in the quantification of a therapeutic monoclonal antibody in human plasma. Bioanalysis 2015; 6:1767-79. [PMID: 25157484 DOI: 10.4155/bio.14.111] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Monoclonal antibodies are the fastest growing class of protein therapeutics. Ligand-binding assays have been the technique of choice for the quantification of these large proteins; however, LC-MS and more recently LC-HRMS have been gaining momentum as robust alternatives for the bioanalysis of antibodies in biological matrices. RESULTS Optimization of sample preparation and LC-HRMS analysis in MRM(HR) mode has allowed us to develop a highly specific dual-peptide targeted assay for the quantification of Rituximab, in human plasma. The linearity of the assay was established from 1.0 to 200 µg/ml for both light and heavy chain surrogate peptides, with accuracy and precision within 15%. CONCLUSION LC-HRMS can be an effective tool for the quantification of monoclonal antibodies in regulated bioanalysis.
Collapse
|
18
|
Bults P, van de Merbel NC, Bischoff R. Quantification of biopharmaceuticals and biomarkers in complex biological matrices: a comparison of liquid chromatography coupled to tandem mass spectrometry and ligand binding assays. Expert Rev Proteomics 2015; 12:355-74. [DOI: 10.1586/14789450.2015.1050384] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
19
|
Absolute and multiplex quantification of antibodies in serum using PSAQ™ standards and LC-MS/MS. Bioanalysis 2015; 7:1237-51. [DOI: 10.4155/bio.15.56] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Background: In preclinical studies, monoclonal antibodies (mAbs) are traditionally assayed by ligand-binding-assays. Recently, quantitative liquid chromatography mass spectrometry (MS)-based assays have emerged which circumvent a number of challenges. These assays may also be multiplex, making them potentially compatible with pharmacokinetic assays for combined antibody therapies. Materials & methods: We combined a quantitative MS-based approach with the protein standard for absolute quantification (PSAQ™) strategy to simultaneously quantify three mAb variants presenting minor sequence differences. Stable isotopically labeled mAbs were produced and used as quantification standards. Titration curves were performed to assess the analytical performances of the method. LC-MS/MS and ELISA data were cross-compared. Results: The approach presented provides similar accuracy and precision than ELISA, while being multiplex and faster to develop. It has applications at all stages of the pharmaceutical development.
Collapse
|
20
|
PK study of octreotide based on LC–MS/MS combining protein precipitation and impurity extraction technique. Bioanalysis 2015; 7:885-94. [DOI: 10.4155/bio.15.22] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Aim: To establish a robust methodology for quantitative analysis of therapeutic peptide in biological samples. Materials & Methods: Octreotide was chosen as a model therapeutic peptide, and oxidized-octreotide was synthesized as internal standard. Protein precipitation combining liquid-liquid extraction technique was adopted to enhance the recovery and reduce the endogenous interferences effectively. A LC–MS/MS method for the quantification of octreotide in plasma has been optimized and validated according to FDA guidelines. Results: Linearity, selectivity, accuracy, precision, stability, matrix effect and recovery were within bioanalytical method validation acceptance criteria as FDA guidelines. The methodology was then successfully applied into the studies for octreotide. Conclusion: This robust methodology would be useful for the PK studies for octreotide and other therapeutic peptides.
Collapse
|
21
|
|
22
|
An exploratory universal LC–MS/MS assay for bioanalysis of hinge region-stabilized human IgG4 mAbs in clinical studies. Bioanalysis 2014; 6:1747-58. [DOI: 10.4155/bio.14.64] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background: Due to the increasing number of monoclonal antibody (mAb) drug candidates entering clinical development, bioanalytical laboratories can benefit from generic liquid chromatography–tandem mass spectrometry (LC–MS/MS) assays capable of quantifying a variety of human mAb-based therapeutic drug candidates in plasma/serum samples from clinical studies. Results: We have developed and evaluated an exploratory LC–MS/MS assay capable of quantifying hinge region-stabilized IgG4 therapeutic mAb drugs and drug candidates in clinical samples. The exploratory assay is based upon a single ‘universal IgG4’ surrogate peptide. Conclusion: The novel exploratory LC–MS/MS assay reported herein, upon further refinement and full validation, is predicted to enable bioanalytical scientists to quantify all hinge region-stabilized human IgG4 therapeutic mAbs in human studies without having to develop a new assay for every new stabilized IgG4 mAb entering clinical development.
Collapse
|
23
|
Applications of low-flow LC–SRM for the analysis of large molecules in pharmaceutical R&D. Bioanalysis 2014; 6:1859-67. [DOI: 10.4155/bio.14.141] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Although ligand-binding assays are frequently employed to measure large molecules, the use of LC–SRM assays is increasingly popular due to the inherent selectivity advantage and the ability to operate without exquisitely selective antibodies. Until recently LC–SRM assays have been unable to compete with ligand-binding assays in terms of sensitivity. However, the use of low-flow chromatography prior to mass spectrometry has played a crucial role in increasing the sensitivity of LC–SRM platforms and enabling measurements of large molecules that had previously been unmeasurable. In this article, we highlight some technical advances, describe strategies for employing low-flow chromatography, and review recent literature that describes implementation of low-flow LC–SRM to support large-molecule analysis in pharmaceutical R&D.
Collapse
|
24
|
The integration of ligand binding and LC-MS-based assays into bioanalytical strategies for protein analysis. Bioanalysis 2014; 6:1827-41. [DOI: 10.4155/bio.14.128] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Both LBAs and LC–MS-based assays are reviewed and summarized for applications in quantitative protein analysis. A strategy for platform selection is proposed based on several factors that contribute to the complexities of bioanalysis of biologics. Protein types, multiple co-existing forms, post-translational modifications, and affinities to ADA, targets, and endogenous proteins need to be considered when selecting the most appropriate platform. Other factors, such as intended use of data, assay sensitivity, available reagents, and multiple analytes also impact on the choice of bioanalytical platform. At BMS, strategies for the seamless integration of both platforms are being implemented to provide not only PK/PD data of the molecules but also useful information of the amino acid structure and functional relationship of the proteins.
Collapse
|
25
|
Jiang H, Xu W, Titsch CA, Furlong MT, Dodge R, Voronin K, Allentoff A, Zeng J, Aubry AF, DeSilva BS, Arnold ME. Innovative Use of LC-MS/MS for Simultaneous Quantitation of Neutralizing Antibody, Residual Drug, and Human Immunoglobulin G in Immunogenicity Assay Development. Anal Chem 2014; 86:2673-80. [DOI: 10.1021/ac5001465] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- Hao Jiang
- Analytical and Bioanalytical Development and ‡ Discovery Chemistry
Synthesis, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Weifeng Xu
- Analytical and Bioanalytical Development and ‡ Discovery Chemistry
Synthesis, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Craig A. Titsch
- Analytical and Bioanalytical Development and ‡ Discovery Chemistry
Synthesis, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Michael T. Furlong
- Analytical and Bioanalytical Development and ‡ Discovery Chemistry
Synthesis, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Robert Dodge
- Analytical and Bioanalytical Development and ‡ Discovery Chemistry
Synthesis, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Kimberly Voronin
- Analytical and Bioanalytical Development and ‡ Discovery Chemistry
Synthesis, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Alban Allentoff
- Analytical and Bioanalytical Development and ‡ Discovery Chemistry
Synthesis, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Jianing Zeng
- Analytical and Bioanalytical Development and ‡ Discovery Chemistry
Synthesis, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Anne-Françoise Aubry
- Analytical and Bioanalytical Development and ‡ Discovery Chemistry
Synthesis, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Binodh S. DeSilva
- Analytical and Bioanalytical Development and ‡ Discovery Chemistry
Synthesis, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Mark E. Arnold
- Analytical and Bioanalytical Development and ‡ Discovery Chemistry
Synthesis, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| |
Collapse
|